Generation of isogenic models of Angelman syndrome and Prader-Willi syndrome in CRISPR/Cas9-engineered human embryonic stem cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 02 10 2023
accepted: 20 09 2024
medline: 2 11 2024
pubmed: 2 11 2024
entrez: 1 11 2024
Statut: epublish

Résumé

Angelman syndrome (AS) and Prader-Willi syndrome (PWS), two distinct neurodevelopmental disorders, result from loss of expression from imprinted genes in the chromosome 15q11-13 locus most commonly caused by a megabase-scale deletion on either the maternal or paternal allele, respectively. Each occurs at an approximate incidence of 1/15,000 to 1/30,000 live births and has a range of debilitating phenotypes. Patient-derived induced pluripotent stem cells (iPSCs) have been valuable tools to understand human-relevant gene regulation at this locus and have contributed to the development of therapeutic approaches for AS. Nonetheless, gaps remain in our understanding of how these deletions contribute to dysregulation and phenotypes of AS and PWS. Variability across cell lines due to donor differences, reprogramming methods, and genetic background make it challenging to fill these gaps in knowledge without substantially increasing the number of cell lines used in the analyses. Isogenic cell lines that differ only by the genetic mutation causing the disease can ease this burden without requiring such a large number of cell lines. Here, we describe the development of isogenic human embryonic stem cell (hESC) lines modeling the most common genetic subtypes of AS and PWS. These lines allow for a facile interrogation of allele-specific gene regulation at the chromosome 15q11-q13 locus. Additionally, these lines are an important resource to identify and test targeted therapeutic approaches for patients with AS and PWS.

Identifiants

pubmed: 39485792
doi: 10.1371/journal.pone.0311565
pii: PONE-D-23-32075
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0311565

Informations de copyright

Copyright: © 2024 Gilmore et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

S.J.C. is now an employee of F. Hoffmann-La Roche AG. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Auteurs

Rachel B Gilmore (RB)

Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT, United States of America.
Graduate Program in Biomedical Science, Genetics and Developmental Biology, UConn Health, Farmington, CT, United States of America.

Dea Gorka (D)

Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT, United States of America.
Graduate Program in Biomedical Science, Genetics and Developmental Biology, UConn Health, Farmington, CT, United States of America.

Christopher E Stoddard (CE)

Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT, United States of America.

Pooja Sonawane (P)

Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT, United States of America.
Graduate Program in Biomedical Science, Genetics and Developmental Biology, UConn Health, Farmington, CT, United States of America.

Justin Cotney (J)

Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT, United States of America.
Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States of America.

Stormy J Chamberlain (SJ)

Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT, United States of America.
Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH